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A clade 1 sequence of H5 haemaglutinin from  an Asian Avian H5N1 isolate was used 
as a template to chemically synthetize a codon-optimized version for expression in 
insect cells. When insect cells are infected with the mutK + H5 HA Baculovirus, the 
polyhedrin promoter  will subsecuently direct a high level of expression of the 
mutK+H5 HA protein. After plaque purification and subsecuent scale-up in SF(+) 
cells, the supernatant of the recombinant baculovirus containing the  mutK + H5 HA 
gene was put down as a MSV and designated as “mutK + H5 HA Baculovirus DB  
Master Seed Virus”.
Introduction
Materials and Methods
Characterization
Results
Influenza virus causes an important disease worldwide. Avian Influenza LP 
and HP represent a high risk for poultry producers, and its control is a major 
burden according to sporadic outbreaks which are related to the distribution 
of HP variants. The virus  causes disease in several continents. The control of 
AIV, H5 subtype, remains as a main challenge and different kind of 
vaccines are available. The use of insect cells and baculovirus to produce 
the H5 HA offers the versatility, simplicity, scale-ability and yields of a very 
efficient vaccine producing process.
Conclusions
• A vaccine prototype based on the H5 HA sequence expressed in the 
baculovirus/insect cells system is available.
• Process parameters have been optimized to achieve reproducible and 
relieable yields in the scale of 0.5 L.
• The expressed antigen triggered an immune response when administered 
as an inactivated oil-emulsion to 3 weeks old chickens.
• The antigen was stable upon combination with BEI-inactivated NDV 
and elicited a protective immune response demoNstrated by 
challenge with NDV infectious virus.
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Cell density (A), cell viability (B), and antigen yield (C) using MSV+4 master seed virus at MOI of 0.1. Cell viability dropped down 
after 48 hpi. and the antigen accumulation did not change after 4 dpi.
Antibody levels (HI titres) elicited by 0.5 ml administered 
subcutaneously in 3 weeks old SPF chickens. Representatives 
of several clades and subclade of HPAI H5N1 virus were used 
as antigens. Seroconversion was demonstrated in all cases 
and titres were above 4 Logs base 2 (1:16). A comparative 
priming/boosting application was included for comparison 
(DOA for BES H5 and 10 days old for H5N2 vaccine). 
Antibody levels (ELISA) elicited by 0.5 ml 
administered subcutaneously in weeks 
old SPF chickens. The prototype included 
several amounts of  haemaglutinin per 
dose as indicated. 
Chickens were bled at 2, 4, 5, 6, and 7 
weeks post vaccination to show 
development of the immune response.
Infection with MOI of 0.5 (Green, purple) or 0.1 (Blue, Red). Cell density (A), cell viability (B), and 
antigen yield (C). Cell population reaches densities above 2x10E6, and the antigen yields is the same, 
suggesting that the Optimal Peak Cell Density (OPCD) must be between 2 and 3x10E6.
Estimation of antigen yield using a 
commercial ELISA assay. Values did not change after 
96 hpi (T4), in agreement with previous HAU results.
Diagram depicting the genetic construct inserted into the bacu-
lovirus genome. Stability testing after 5 passages have shown 
the sequence is stable and no further changes where detected.
 
Flanking baculovirus DNA
MutH5 K+. Haemaglutinin HA gene as inserted onto the baculovirus genome.   
(Genbank AY518362)
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Vaccinated chickens were administered with a  combinated 
prototype including 400 HAU of H5 HA and 128 HAU of ND 
KV (both BEI-inactivated). 3 weeks post vaccination the 
animals were challenged with NDV and mortality recorded 
during two weeks. The presence of the H5 HA antigenic 
fraction did not affected the protection conferred by the 
ND fraction as shown in the figure.
Antibody levels (HI titres) elicited by 0.5 ml administered 
subcutaneously in weeks old SPF chickens. The prototype
included several amounts of haemaglutinin per dose as 
indicated. Chickens were bled at 2, 4 and 5 weeks post 
vaccination to show development of the immune response.
Stability analysis shows that the genetic construct 
and the protein are possible to be detected after 5 
serial passages of the Master Seed virus. H5-specific 
primers were used to detect the 1.7 kb fragment (A), 
sequencing is ongoing. A monoclonal H5 HA-
specific antibody was used to detect the mono, di, 
and trimeric forms of the protein (B) whether from 
the first, fifth passage, or a from a representative 
harvest (lane 2, harvest amount used to be obtained 
after 4 dpi).
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In order to test the biological activity of the expressed protein and its ability to trigger an immune 
response, oil/water emulsions of different amounts of the protein were administered to SPF chickens and 
antibodies levels were detected using an ELISA-based system and HI titration. Both approaches were able 
to demonstrate seroconversion and a dose-response curve was observed among the different doses. 
Altogether, results support the feasibility of the genetic contruct and the expression platform to produce 
bulk amounts of biologically active protein.
